Genomics of Drug Sensitivity in Cancer |
Amuvatinib
|
Synonyms |
MP470, MP 470, MP-470
|
Targets |
KIT, PDGFRA, FLT3
|
Target pathway |
Other, kinases
|
PubCHEM ID |
11282283
|
Jsmol |
|
Download molecule |
11282283
|
PUBCHEM IUPAC INCHI |
InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)
|
Smiles |
S=C(N4(CCN(C1(=NC=NC2(=C1OC=3(C=CC=CC2=3))))CC4))NCC6(=CC=5(OCOC=5C=C6))
|
Cluster number |
79
|
calculated LogS |
-5,876
|
Molecular weight |
447,518
|
calculated LogP |
3,8291
|
H-Acceptors |
8
|
H-Donors |
1
|
Ro5 violations |
0
|
Druglikeness |
3,9925
|
DrugScore |
0,46703371084171
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Fish Toxicity |
High FHMT
|
Fish Toxicity2 |
1,5029
|
Rat Acute Toxicity |
2,4475
|
Acute Oral Toxicity |
III
|
Caco-2 Permeability |
Caco2-
|
Caco-2 Permeability2 |
1,0958
|
P-glycoprotein Substrate |
Non-substrate
|
P-glycoprotein Inhibitor |
Non-inhibitor
|
P-glycoprotein Inhibitor2 |
Non-inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Strong inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,5755
|
AMES Toxicity |
AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Non-substrate
|
CYP450 3A4 Inhibitor |
Inhibitor
|
CYP450 2C19 Inhibitor |
Inhibitor
|
CYP450 2C9 Inhibitor |
Inhibitor
|
CYP450 2D6 Inhibitor |
Inhibitor
|
CYP450 1A2 Inhibitor |
Inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Non-required
|
Blood-Brain Barrier |
BBB+
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
Low HBT
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Subcellular localization |
Mitochondria
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-3,4786
|